Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cognate BioServices was a leading CDMO specializing in the development and cGMP manufacturing of autologous and allogeneic cell therapies and gene therapies. The company supported clients from preclinical through commercial stages with expertise in viral vectors, plasmids, cellular immunotherapies including CAR-T/NK/TIL/MIL products. In March/April 2021 it was acquired by Charles River Laboratories for approximately $875 million to expand Charles River’s integrated offerings across the cell/gene therapy value chain.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cognate BioServices.